【摘要】 目的 探討葡萄糖轉(zhuǎn)運(yùn)蛋白Ⅰ型（glucose transporter 1，GLUT1）和腫瘤增殖細(xì)胞核抗原Ki-67在卵巢上皮性腫瘤組織中的表達(dá)及其臨床意義。 方法 收集2000年1月-2008年6月不同卵巢上皮性腫瘤病變患者119例的組織標(biāo)本，采用免疫組織化學(xué)SP二步法檢測腫瘤組織中GLUT1和Ki-67的表達(dá)情況。 結(jié)果 卵巢交界性、惡性上皮性腫瘤灶性或廣泛高表達(dá)GLUT1和Ki-67，其表達(dá)強(qiáng)度有差異。卵巢良性上皮性腫瘤不表達(dá)GLUT1和Ki-67。在卵巢癌中GLUT1及Ki-67的表達(dá)強(qiáng)度與病理分級、臨床分期、預(yù)后有關(guān)。GLUT1表達(dá)強(qiáng)度與病理分型無關(guān)，Ki-67表達(dá)強(qiáng)度與病理分型有關(guān)。 結(jié)論 卵巢上皮性腫瘤組織中GLUT1和Ki-67的表達(dá)具有相關(guān)性，其表達(dá)強(qiáng)度與腫瘤的良惡性質(zhì)和增殖狀態(tài)有關(guān)，二者同時檢測可以全面了解卵巢上皮性腫瘤的性質(zhì)、卵巢癌惡性程度和生物學(xué)行為，對于判斷腫瘤的性質(zhì)和預(yù)后有一定價值。
【Abstract】 Objective To investigate the expression and clinical significance of glucose transporter-1 (GLUT1) and tumor proliferating karyon antigen Ki-67 in epithelial ovarian tumor tissue. Methods Immunohistochemistry SP method was used to detect the expression of GLUT1 and Ki-67 protein in epithelial ovarian tumor tissues from 119 patients diagnosed in our hospital from January 2000 to June 2008. Results The expressions of GLUT1 and Ki-67 had local or abroad higher expressions in the borderline and malignant epithelial ovarian tumor, and the expressive intensity was different. In benign tumors, the expression was negative. The expressive intensity of GLUT1 and Ki-67 had correlation with the grade, stage, and prognosis in malignant tumors. The expressive intensity of GLUT1 had no correlation with the type of malignant tumors, while Ki-67 related to the pathological types. Conclusion The expressions of GLUT1 and Ki-67 have relativity. The expressive intensity of GLUT1 and Ki-67 relates to the character and proliferation of epithelial ovarian tumors. The combined detection GLUT1 and Ki-67 is helpful to know the character of epithelial ovarian tumors, the malignant degree and biologic behavior of ovarian carcinoma, which is useful in estimating the character and prognosis of epithelial ovarian tumors.
引用本文： 王安群,劉靜之,楊永紅,謝剛,謝春燕,原慶會,陳中書,余江,吳小戈,劉盛均. 葡萄糖轉(zhuǎn)運(yùn)蛋白Ⅰ型與腫瘤增殖細(xì)胞核抗原在卵巢上皮性腫瘤中的表達(dá)及意義. 華西醫(yī)學(xué), 2011, 26(1): 63-65. doi: 復(fù)制
| 1. | Rudlowski C, Moser M, Becker AJ, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer[J]. Oncology, 2004, 66(5): 404-410. |
| 2. | Khouja MH, Baekelandt M, Nesland JM, et al. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma[J]. Int J Gynecol Pathol, 2007, 26(4): 418-425. |
| 3. | Wood IS, Trayhum P. Glucose transporters (GLUT1 and SGLT): expanded families of sugar transpost proteins[J]. Br J Nutr, 2003, 89(1): 3-9. |
| 4. | Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter GLUT1 in human cancers[J]. Cancer Res, 1996, 56(5): 1164-1167. |
| 5. | 蔡昱, 邵淑麗. GLUT1研究進(jìn)展[J]. 國外醫(yī)學(xué)?腫瘤學(xué)分冊, 2004, 31(增刊): 50-51. |
| 6. | Kalir T, Wang BY, Goldfischer M, et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia[J]. Cancer, 2002, 94(4): 1078-1082. |
| 7. | Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis[J]. Cancer, 1998, 83(1): 34-40. |
| 8. | Cantuaria G, Magalhaes A, Angioli R, et al. Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma [J]. Cancer, 2000, 88(2): 381-388. |
| 9. | 顏琳, 吳緒峰, 陳惠禎. PTEN和Ki-67在上皮性卵巢癌中的表達(dá)及意義[J]. 現(xiàn)代腫瘤醫(yī)學(xué), 2005, 13(2): 151-153. |
| 10. | 任瓊珍, 錢志紅, 胡建銘. Ki-67在卵巢癌中的表達(dá)及意義[J]. 蘇州大學(xué)學(xué)報, 2006, 26(2): 321. |
- 1. Rudlowski C, Moser M, Becker AJ, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer[J]. Oncology, 2004, 66(5): 404-410.
- 2. Khouja MH, Baekelandt M, Nesland JM, et al. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma[J]. Int J Gynecol Pathol, 2007, 26(4): 418-425.
- 3. Wood IS, Trayhum P. Glucose transporters (GLUT1 and SGLT): expanded families of sugar transpost proteins[J]. Br J Nutr, 2003, 89(1): 3-9.
- 4. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter GLUT1 in human cancers[J]. Cancer Res, 1996, 56(5): 1164-1167.
- 5. 蔡昱, 邵淑麗. GLUT1研究進(jìn)展[J]. 國外醫(yī)學(xué)?腫瘤學(xué)分冊, 2004, 31(增刊): 50-51.
- 6. Kalir T, Wang BY, Goldfischer M, et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia[J]. Cancer, 2002, 94(4): 1078-1082.
- 7. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis[J]. Cancer, 1998, 83(1): 34-40.
- 8. Cantuaria G, Magalhaes A, Angioli R, et al. Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma [J]. Cancer, 2000, 88(2): 381-388.
- 9. 顏琳, 吳緒峰, 陳惠禎. PTEN和Ki-67在上皮性卵巢癌中的表達(dá)及意義[J]. 現(xiàn)代腫瘤醫(yī)學(xué), 2005, 13(2): 151-153.
- 10. 任瓊珍, 錢志紅, 胡建銘. Ki-67在卵巢癌中的表達(dá)及意義[J]. 蘇州大學(xué)學(xué)報, 2006, 26(2): 321.